secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2022-04-25T23:59:59+00:00
Accession:  0001104659-22-049317
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond Therapeutics discontinues BDTX-189, cuts workforce 30% to extend cash runway into Q3 2024
--------------------------------------------------------------------------------

- Discontinued BDTX-189 due to rapid evolution of NSCLC treatment landscape (EGFR/HER2 Exon 20 insertions).
- Reduced workforce by ~30% to increase operational efficiency and extend cash runway.
- Cash runway extended into Q3 2024; $209M in cash, equivalents, and investments as of Dec 31, 2021.
- Prioritized BDTX-1535 (Phase 1 for GBM/NSCLC) with clinical data update expected in 2023.
- Prioritized BDTX-4933 (BRAF inhibitor); IND submission expected in first half of 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000110465922049317/0001104659-22-049317-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000110465922049317/tm2213442d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-049317

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer